{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:43Z","timestamp":1793400703200,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:00:00Z","timestamp":1497916800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00280-017-3349-y","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T07:36:26Z","timestamp":1497944186000},"page":"295-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes"],"prefix":"10.1007","volume":"80","author":[{"given":"Dale R.","family":"Miles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1657-7600","authenticated-orcid":false,"given":"Steven A.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Milwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifah","family":"Yaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,20]]},"reference":[{"key":"3349_CR1","unstructured":"Guideline IHT (2005) The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs E14. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002879.pdf . Accessed 30 Dec 2016"},{"issue":"11","key":"3349_CR2","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","volume":"89","author":"YG Yap","year":"2003","unstructured":"Yap YG, Camm AJ (2003) Drug induced QT prolongation and torsades de pointes. Heart 89(11):1363\u20131372","journal-title":"Heart"},{"issue":"2","key":"3349_CR3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0008-6363(00)00119-X","volume":"47","author":"W Haverkamp","year":"2000","unstructured":"Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A (2000) The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Cardiovasc Res 47(2):219\u2013233","journal-title":"Cardiovasc Res"},{"issue":"2","key":"3349_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/CIRCEP.108.789081","volume":"2","author":"AO Grant","year":"2009","unstructured":"Grant AO (2009) Cardiac ion channels. Circ Arrhythm Electrophysiol 2(2):185\u2013194. doi: 10.1161\/CIRCEP.108.789081","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"22","key":"3349_CR5","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","volume":"25","author":"EL Strevel","year":"2007","unstructured":"Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25(22):3362\u20133371. doi: 10.1200\/JCO.2006.09.6925","journal-title":"J Clin Oncol"},{"issue":"2","key":"3349_CR6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pcad.2010.05.005","volume":"53","author":"JM Brell","year":"2010","unstructured":"Brell JM (2010) Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy. Prog Cardiovasc Dis 53(2):164\u2013172","journal-title":"Prog Cardiovasc Dis"},{"key":"3349_CR7","doi-asserted-by":"crossref","unstructured":"Curigliano G, Spitaleri G, De Braud F, Cardinale D, Cipolla C, Civelli M, Colombo N, Colombo A, Locatelli M, Goldhirsch A (2009) QTc prolongation assessment in anticancer drug development: clinical and methodological issues. ecancermedicalscience 3:130","DOI":"10.3332\/ecancer.2008.130"},{"issue":"1","key":"3349_CR8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1476-5381.2009.00427.x","volume":"159","author":"V Salvi","year":"2010","unstructured":"Salvi V, Karnad DR, Panicker GK, Kothari S (2010) Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol 159(1):34\u201348","journal-title":"Br J Pharmacol"},{"issue":"3","key":"3349_CR9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/14740338.7.3.305","volume":"7","author":"N Sarapa","year":"2008","unstructured":"Sarapa N, Britto MR (2008) Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin Drug Saf 7(3):305\u2013318","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"3349_CR10","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10(12):2298\u20132308","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"3349_CR11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1089\/thy.2009.0417","volume":"20","author":"C Capp","year":"2010","unstructured":"Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL (2010) Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 20(8):863\u2013871","journal-title":"Thyroid"},{"issue":"1","key":"3349_CR12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1593\/neo.08916","volume":"11","author":"G Cassinelli","year":"2009","unstructured":"Cassinelli G, Favini E, Degl\u2019Innocenti D, Salvi A, De Petro G, Pierotti MA, Zunino F, Borrello MG, Lanzi C (2009) RET\/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and \u03b2-catenin nuclear translocation. Neoplasia 11(1):10\u201321","journal-title":"Neoplasia"},{"issue":"24","key":"3349_CR13","first-page":"7284","volume":"62","author":"F Carlomagno","year":"2002","unstructured":"Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Can Res 62(24):7284\u20137290","journal-title":"Can Res"},{"key":"3349_CR14","unstructured":"COMETRIQ(R) [package insert] (2016) Exelixis Inc., South San Francisco. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/203756s002lbl.pdf . Accessed 30 Dec 2016"},{"key":"3349_CR15","unstructured":"US Food and Drug Administration CfDEaR (2012) Approval package for application number 203756Orig1s000 for cabozantinib (COMETRIQ(R)). Clin Pharmacol Biopharm Rev(s). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203756Orig1s000ClinPharmR.pdf . Accessed 30 Dec 2016"},{"issue":"1","key":"3349_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40262-015-0295-x","volume":"55","author":"D Miles","year":"2016","unstructured":"Miles D, Jumbe NL, Lacy S, Nguyen L (2016) Population pharmacokinetic model of cabozantinib in patients with medullary thyroid carcinoma and its application to an exposure-response analysis. Clin Pharmacokinet 55(1):93\u2013105. doi: 10.1007\/s40262-015-0295-x","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3349_CR17","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/jcph.510","volume":"55","author":"L Nguyen","year":"2015","unstructured":"Nguyen L, Holland J, Miles D, Engel C, Benrimoh N, O\u2019Reilly T, Lacy S (2015) Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol 55(9):1012\u20131023. doi: 10.1002\/jcph.510","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"3349_CR18","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/jcph.526","volume":"55","author":"L Nguyen","year":"2015","unstructured":"Nguyen L, Holland J, Mamelok R, Laberge MK, Grenier J, Swearingen D, Armas D, Lacy S (2015) Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol 55(11):1293\u20131302. doi: 10.1002\/jcph.526","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"3349_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40262-016-0461-9","volume":"56","author":"SA Lacy","year":"2017","unstructured":"Lacy SA, Miles DR, Nguyen LT (2017) Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clin Pharmacokinet. 56(5):477\u2013491. doi: 10.1007\/s40262-016-0461-9","journal-title":"Clin Pharmacokinet."},{"issue":"2","key":"3349_CR20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0092-8674(95)90340-2","volume":"81","author":"MC Sanguinetti","year":"1995","unstructured":"Sanguinetti MC, Jiang C, Curran ME, Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: hERG encodes the IKr potassium channel. Cell 81(2):299\u2013307","journal-title":"Cell"},{"issue":"7083","key":"3349_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature04710","volume":"440","author":"MC Sanguinetti","year":"2006","unstructured":"Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440(7083):463\u2013469. doi: 10.1038\/nature04710","journal-title":"Nature"},{"issue":"1","key":"3349_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.vascn.2005.03.008","volume":"52","author":"BA Wible","year":"2005","unstructured":"Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM (2005) HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 52(1):136\u2013145. doi: 10.1016\/j.vascn.2005.03.008","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"10","key":"3349_CR23","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/01.CIR.94.10.2572","volume":"94","author":"J Kiehn","year":"1996","unstructured":"Kiehn J, Lacerda AE, Wible B, Brown AM (1996) Molecular physiology and pharmacology of HERG single-channel currents and block by dofetilide. Circulation 94(10):2572\u20132579","journal-title":"Circulation"},{"issue":"5","key":"3349_CR24","doi-asserted-by":"crossref","first-page":"H2534","DOI":"10.1152\/ajpheart.1997.273.5.H2534","volume":"273","author":"S Mohammad","year":"1997","unstructured":"Mohammad S, Zhou Z, Gong Q, January CT (1997) Blockage of the HERG human cardiac K\u00a0+\u00a0channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol-Heart Circ Physiol 273(5):H2534\u2013H2538","journal-title":"Am J Physiol-Heart Circ Physiol"},{"key":"3349_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fphar.2014.00203","volume":"5","author":"T Danker","year":"2014","unstructured":"Danker T, Moller C (2014) Early identification of hERG liability in drug discovery programs by automated patch clamp. Front Pharmacol 5:203. doi: 10.3389\/fphar.2014.00203","journal-title":"Front Pharmacol"},{"key":"3349_CR26","unstructured":"US Food and Drug Administration CfDEaR (2012) Approval package for application number 203756Orig1s000 for cabozantinib (COMETRIQ(R)). Pharmacol Rev. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203756Orig1s000PharmR.pdf . Accessed 30 Dec 2016"},{"key":"3349_CR27","unstructured":"US Food and Drug Administration CfDEaR (2005) Guidance for industry: E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm073153.pdf . Accessed 30 Dec 2016"},{"issue":"22","key":"3349_CR28","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.1158\/1078-0432.CCR-09-1521","volume":"15","author":"CL Bello","year":"2009","unstructured":"Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L (2009) Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res 15(22):7045\u20137052. doi: 10.1158\/1078-0432.CCR-09-1521","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3349_CR29","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00280-013-2160-7","volume":"71","author":"D Sonnichsen","year":"2013","unstructured":"Sonnichsen D, Dorer DJ, Cortes J, Talpaz M, Deininger MW, Shah NP, Kantarjian HM, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG (2013) Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol 71(6):1599\u20131607. doi: 10.1007\/s00280-013-2160-7","journal-title":"Cancer Chemother Pharmacol"},{"issue":"29","key":"3349_CR30","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, M\u00fcller SP, Sch\u00f6ffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639\u20133646","journal-title":"J Clin Oncol"},{"issue":"6","key":"3349_CR31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/europace\/eun028","volume":"10","author":"S Genovesi","year":"2008","unstructured":"Genovesi S, Dossi C, Vigano MR, Galbiati E, Prolo F, Stella A, Stramba-Badiale M (2008) Electrolyte concentration during haemodialysis and QT interval prolongation in uraemic patients. Europace 10(6):771\u2013777. doi: 10.1093\/europace\/eun028","journal-title":"Europace"},{"issue":"4","key":"3349_CR32","first-page":"288","volume":"6","author":"B Hosmane","year":"2006","unstructured":"Hosmane B, Locke C, Morris D (2006) QT interval correction for heart rate. J Appl Res Clin Exp Ther 6(4):288\u2013299","journal-title":"J Appl Res Clin Exp Ther"},{"issue":"7","key":"3349_CR33","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1177\/0091270010378408","volume":"51","author":"CW Torn\u00f8e","year":"2011","unstructured":"Torn\u00f8e CW, Garnett CE, Wang Y, Florian J, Li M, Gobburu JV (2011) Creation of a knowledge management system for QT analyses. J Clin Pharmacol 51(7):1035\u20131042","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"3349_CR34","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.1993.03500120051025","volume":"269","author":"PK Honig","year":"1993","unstructured":"Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR (1993) Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 269(12):1513\u20131518","journal-title":"JAMA"},{"issue":"4","key":"3349_CR35","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3109\/0886022X.2012.656561","volume":"34","author":"F Afshinnia","year":"2012","unstructured":"Afshinnia F, Doshi H, Rao PS (2012) The effect of different dialysate magnesium concentrations on QTc dispersion in hemodialysis patients. Ren Fail 34(4):408\u2013412","journal-title":"Ren Fail"},{"issue":"6","key":"3349_CR36","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ahj.2012.02.023","volume":"163","author":"CE Garnett","year":"2012","unstructured":"Garnett CE, Zhu H, Malik M, Fossa AA, Zhang J, Badilini F, Li J, Darpo B, Sager P, Rodriguez I (2012) Methodologies to characterize the QT\/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects. Am Heart J 163(6):912\u2013930. doi: 10.1016\/j.ahj.2012.02.023","journal-title":"Am Heart J"},{"issue":"3","key":"3349_CR37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/heart.87.3.220","volume":"87","author":"M Malik","year":"2002","unstructured":"Malik M, F\u00e4rbom P, Batchvarov V, Hnatkova K, Camm A (2002) Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 87(3):220\u2013228","journal-title":"Heart"},{"issue":"6","key":"3349_CR38","doi-asserted-by":"crossref","first-page":"H2356","DOI":"10.1152\/ajpheart.00860.2001","volume":"282","author":"VN Batchvarov","year":"2002","unstructured":"Batchvarov VN, Ghuran A, Smetana P, Hnatkova K, Harries M, Dilaveris P, Camm AJ, Malik M (2002) QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol-Heart Circ Physiol 282(6):H2356\u2013H2363","journal-title":"Am J Physiol-Heart Circ Physiol"},{"issue":"2","key":"3349_CR39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","volume":"112","author":"P Ghatalia","year":"2015","unstructured":"Ghatalia P, Je Y, Kaymakcalan M, Sonpavde G, Choueiri T (2015) QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 112(2):296\u2013305","journal-title":"Br J Cancer"},{"key":"3349_CR40","unstructured":"US Food and Drug Administration CfDEaR (August 2010) Application number 022405Orig1s000 for vandetanib (CAPRELSA(R)). Pharmacol Rev(s). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022405Orig1s000PharmR.pdf . Accessed 30 Dec 2016"},{"issue":"3","key":"3349_CR41","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1158\/1078-0432.CCR-12-2353","volume":"19","author":"NG Chau","year":"2013","unstructured":"Chau NG, Haddad RI (2013) Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res 19(3):524\u2013529. doi: 10.1158\/1078-0432.CCR-12-2353","journal-title":"Clin Cancer Res"},{"key":"3349_CR42","unstructured":"ICLUSIG(R) [package insert] (2016) ARIAD Pharmaceuticals Inc., Cambridge. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/203469s022lbl.pdf . Accessed 30 Dec 2016"},{"key":"3349_CR43","unstructured":"PROLIA(R) [summary of product characteristics] (2017) AMGEN LIMITED, Cambridge, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002173\/WC500110381.pdf . Accessed 29 Apr 2017"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3349-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3349-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3349-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T06:01:40Z","timestamp":1569477700000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3349-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,20]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3349"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3349-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,20]]}}}